Tubulysin B is primarily recognized for its potent antitumor properties, making it a significant compound in cancer research. It functions by disrupting microtubule dynamics, which are crucial for cell division and proliferation. This mechanism effectively inhibits the growth of cancer cells, leading to their eventual death. Due to its high cytotoxicity, Tubulysin B is often explored as a payload in antibody-drug conjugates (ADCs), where it can be targeted specifically to tumor cells, minimizing damage to healthy tissues. Its application in preclinical studies has shown promising results in combating various types of cancers, including those resistant to conventional therapies. Researchers are also investigating its potential in combination with other treatments to enhance efficacy and overcome drug resistance.